Larimar Therapeutics, Inc. (LRMR) Tops Q3 EPS by 1c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q3 EPS of ($0.21), $0.01 better than the analyst estimate of ($0.22).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Deutsche Bank monitors UK auto sales as Chinese exports grow
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04